Fulcrum Therapeutics, Inc. (FULC) vs Immuneering Corporation (IMRX)

Fulcrum Therapeutics, Inc. and Immuneering Corporation are both Biotechnology companies. Fulcrum Therapeutics, Inc. and Immuneering Corporation are of similar size ($288.8M and $280.8M). Fulcrum Therapeutics, Inc. grew revenue faster over the last twelve months: 1,939.8% against −84.8%. Across the 13 metrics below, Fulcrum Therapeutics, Inc. leads on 9 and Immuneering Corporation on 4.

Valuation

Metric FULC IMRX Biotechnology median
P/E n/m n/m 7.88
P/S 3.46 871.47 11.47
P/B 0.92 1.45 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.35 n/m 0.74
EV/Sales (0.41) 398.60 10.73
Earnings yield (32.35%) (24.36%) (28.84%)
Free cash flow yield (23.03%) (20.63%) (23.03%)

Profitability

Metric FULC IMRX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (32.38%) (52.15%) (57.72%)
Return on assets (30.75%) (47.31%) (49.22%)
Return on invested capital 0.00% (97.14%) 0.00%

Growth

Metric FULC IMRX Biotechnology median
Revenue growth (TTM) 1,939.80% (84.76%) 5.64%
EPS growth (last fiscal year) (637.50%) 37.75% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FULC IMRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 31.35 19.47 4.73
Net debt to EBITDA 4.23 2.94 0.96

Dividend

Metric FULC IMRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric FULC IMRX Biotechnology median
Market cap 288.79m 280.79m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack